Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
September 2024—BD and Quest Diagnostics announced a worldwide collaboration agreement to develop, manufacture, and commercialize flow-cytometry–based companion diagnostics intended to help select the best treatment for patients with cancer and other diseases. The joint offerings will range from exploratory panel development to the manufacturing and distribution of FDA-approved diagnostic kits.
September 2024—Sakura Finetek Europe announced the launch of the Tissue-Tek xPrint LP laser cassette printer. Features of the laser printer include high-definition barcode printing at 2,500 dpi and a printing speed of up to 2.5 seconds per cassette. It is designed to print on Tissue-Tek Paraform cassettes of any color, without the need for calibration or additional setup. Print quality is robust and resistant to heat, alcohol, xylene, acid, and scratching, as well as other common laboratory conditions. The printer supports a wide range of content, including logos, barcodes, QR codes, data matrices, and text that can be displayed in the Windows system.
September 2024—Illumina announced Food and Drug Administration approval of its in vitro diagnostic TruSight Oncology Comprehensive test and its first two companion diagnostic indications. This single test interrogates more than 500 genes to profile a patient’s solid tumor, helping to increase the likelihood of identifying an immuno-oncology biomarker or clinically actionable biomarkers that enable targeted therapy options or clinical trial enrollment.
September 2024—Verichem Laboratories now offers multilevel calibration verification materials for creatine kinase activity as part of its liquid-stable, ready-to-use Enzyme ER Verifier kit. The calibration verifiers are intended to be treated as patient specimens and are available for use on a variety of wet clinical chemistry systems, including from Beckman Coulter, Abbott, Siemens Healthineers, and Roche. The kit contains 5 mL of material for each of the six levels and is stable for 18 months from the manufacturing date.
September 2024—Guardant Health announced FDA approval of the company’s Shield blood test for colorectal cancer screening in adults who are 45 and older and at average risk for the disease. It is the first blood test to be approved by the FDA as a primary screening option for CRC and that meets performance requirements for Medicare coverage.
August 2024—BioPorto Diagnostics unveiled its ProNephro AKI (NGAL) test at ADLM 2024, July 28–Aug. 1, in Chicago. The FDA 510(k)-cleared test is the first acute kidney injury biomarker test cleared for pediatric use (ages 3 months through 21 years) in the United States.
August 2024—Horiba announced that it has expanded its compact hematology instrument range with the launch of three models now with erythrocyte sedimentation rate onboard. The Yumizen H550E (autoloader), H500E CT (closed tube), and H500E OT (open tube) offer combined testing for CBC with differential and ESR results from whole blood in 60 seconds.
August 2024—Machaon Diagnostics has updated its genetic panel for detecting hemophagocytic lymphohistiocytosis. The HLH genetic panel 3.0 sequences 32 genes to reflect the most current understanding of HLH in the scientific literature and includes UNC13D inversion. The panel has a turnaround time of 48 hours. Draw kits are available.
August 2024—Bio-Rad Laboratories has launched its Exact Diagnostics GBS positive and negative run controls. The independent quality controls are intended to be used with group B streptococcus molecular assays for evaluating assay performance and testing operator proficiency.
August 2024—Sysmex America announced on July 9 that longtime health care executive Dan Zortman has been named the company’s new CEO. Andy Hay, who has served as CEO since 2021, will continue to serve as chairman and president of Sysmex America with a focus on the company’s emerging Hinotori surgical robotic system business.
